Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Dendritic Cells (DCs) and Cancer Immunotherapy
share announcement

Dendritic Cells (DCs) and Cancer Immunotherapy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 404

Special Issue Editor

Dr. Aimin Jiang

E-Mail Website
Guest Editor
1. Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health System, Detroit, MI, USA
2. Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA
Interests: dendritic cell vaccine; cancer immunotherapy; tumor immunity; cross-presentation; CD8 T cell immunity; exosomes

Special Issue Information

Dear Colleagues,

Dendritic cells (DCs) are the most potent antigen-presenting cells (APC) that efficiently cross-present tumor-associated antigens (TAAs) and prime tumor antigen-specific CD8 T cells to control tumors. This specific functionality of DCs makes the DC-based vaccines one of the leading strategies for cancer immunotherapy. However, tumors often promote the tolerogenic function of host DCs to suppress anti-tumor immunity, limiting the success of the DC-based cancer vaccines.

There are several obstacles in the success of DC vaccines, i.e., tumor-mediated immunosuppression and the functional limitations of in vitro differentiated DCs. DC-derived exosomes have been considered as an alternative to cell-free therapeutic vaccines. In vivo DC-targeted vaccines and the use of naturally circulating blood DCs also offer promising alternatives to in vitro cultured DCs. There are critical gaps in our understanding of even the basic biology of these approaches, such as how DCexos and different subsets of DCs prime T cells, thus hindering their translation into clinical applications. Similarly, there is a need for a better understanding of how DCs interact with other DCs, B cells, and NK cells to fully unleash the potential of the DC-based vaccines.

This Special Issue on developing cancer vaccines welcomes new research articles and reviews on all aspects of dendritic cells and their roles in vaccine development and cancer immunotherapy.

Dr. Aimin Jiang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dendritic cell vaccine
  • cancer immunotherapy
  • immune checkpoint blockade
  • tumor immunity
  • CD8 T cell immunity
  • exosomes

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 1935 KiB  
Article
β-Catenin in Dendritic Cells Negatively Regulates CD8 T Cell Immune Responses through the Immune Checkpoint Molecule Tim-3
by Chunmei Fu, Jie Wang, Tianle Ma, Congcong Yin, Li Zhou, Björn E. Clausen, Qing-Sheng Mi and Aimin Jiang
Vaccines 2024, 12(5), 460; https://doi.org/10.3390/vaccines12050460 - 25 Apr 2024
Viewed by 273
Abstract
Recent studies have demonstrated that β-catenin in dendritic cells (DCs) serves as a key mediator in promoting both CD4 and CD8 T cell tolerance, although the mechanisms underlying how β-catenin exerts its functions remain incompletely understood. Here, we report that activation of β-catenin [...] Read more.
Recent studies have demonstrated that β-catenin in dendritic cells (DCs) serves as a key mediator in promoting both CD4 and CD8 T cell tolerance, although the mechanisms underlying how β-catenin exerts its functions remain incompletely understood. Here, we report that activation of β-catenin leads to the up-regulation of inhibitory molecule T-cell immunoglobulin and mucin domain 3 (Tim-3) in type 1 conventional DCs (cDC1s). Using a cDC1-targeted vaccine model with anti-DEC-205 engineered to express the melanoma antigen human gp100 (anti-DEC-205-hgp100), we demonstrated that CD11c-β-cateninactive mice exhibited impaired cross-priming and memory responses of gp100-specific CD8 T (Pmel-1) cells upon immunization with anti-DEC-205-hgp100. Single-cell RNA sequencing (scRNA-seq) analysis revealed that β-catenin in DCs negatively regulated transcription programs for effector function and proliferation of primed Pmel-1 cells, correlating with suppressed CD8 T cell immunity in CD11c-β-cateninactive mice. Further experiments showed that treating CD11c-β-cateninactive mice with an anti-Tim-3 antibody upon anti-DEC-205-hgp100 vaccination led to restored cross-priming and memory responses of gp100-specific CD8 T cells, suggesting that anti-Tim-3 treatment likely synergizes with DC vaccines to improve their efficacy. Indeed, treating B16F10-bearing mice with DC vaccines using anti-DEC-205-hgp100 in combination with anti-Tim-3 treatment resulted in significantly reduced tumor growth compared with treatment with the DC vaccine alone. Taken together, we identified the β-catenin/Tim-3 axis as a potentially novel mechanism to inhibit anti-tumor CD8 T cell immunity and that combination immunotherapy of a DC-targeted vaccine with anti-Tim-3 treatment leads to improved anti-tumor efficacy. Full article
(This article belongs to the Special Issue Dendritic Cells (DCs) and Cancer Immunotherapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop